NeuroOne Medical Technologies (NMTC) 10-Q 14 May 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2020	May 08, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	NEUROONE MEDICAL TECHNOLOGIES Corp
Entity Central Index Key	0001500198
Amendment Flag	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	000-54716
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity Common Stock, Shares Outstanding		16,154,122

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Current assets:
Cash	$ 747,244	$ 260,749
Prepaid and other assets	81,305	41,002
Total current assets	828,549	301,751
Right-of-use asset	308,055
Intangible assets, net	167,680	178,838
Property and equipment, net	84,943	52,026
Total assets	1,389,227	532,615
Current liabilities:
Accounts payable	1,077,225	1,152,472
Accrued expenses	291,874	617,721
Convertible promissory notes (Note 7)	4,921,076
Total current liabilities	6,290,175	1,770,193
Lease liability	284,235
Total liabilities	6,574,410	1,770,193
Commitments and contingencies (Note 4)
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2020 and September 30, 2019; no shares issued or outstanding as of March 31, 2020 and September 30, 2019.
Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and September 30, 2019; 14,022,423 and 13,493,705 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively.	14,023	13,494
Additional paid-in capital	18,022,373	15,987,799
Accumulated deficit	(23,221,579)	(17,238,871)
Total stockholders' deficit	(5,185,183)	(1,237,578)
Total liabilities and stockholders' deficit	$ 1,389,227	$ 532,615

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Sep. 30, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	14,022,423	13,493,705
Common stock, shares outstanding	14,022,423	13,493,705

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
General and administrative	$ 1,035,256	$ 1,084,789	$ 2,347,422	$ 1,951,468
Research and development	342,102	436,311	843,921	645,479
Total operating expenses	1,377,358	1,521,100	3,191,343	2,596,947
Loss from operations	(1,377,358)	(1,521,100)	(3,191,343)	(2,596,947)
Interest expense		(20,534)	(2,697,507)	(284,557)
Net valuation change of instruments measured at fair value	31,716	(116,809)	(93,858)	(129,763)
Loss on notes extinguishment		(553,447)		(553,447)
Loss before income taxes	(1,345,642)	(2,211,890)	(5,982,708)	(3,564,714)
Provision for income taxes
Net loss	$ (1,345,642)	$ (2,211,890)	$ (5,982,708)	$ (3,564,714)
Net loss per share:
Basic and diluted	$ (0.10)	$ (0.20)	$ (0.43)	$ (0.34)
Number of shares used in per share calculations:
Basic and diluted	13,904,429	10,971,425	13,780,509	10,360,696

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2018	$ 9,657	$ 6,052,161	$ (10,457,710)	$ (4,395,892)
Balance, shares at Sep. 30, 2018	9,656,505
Issuance of common stock under private placement	$ 330	601,319		601,649
Issuance of common stock under private placements, shares	330,000
Issuance of warrants under private placements		223,351		223,351
Issuance costs related to private placements		(149,316)		(149,316)
Issuance of common stock for consulting services	$ 50	114,950		115,000
Issuance of common stock for consulting services, shares	50,000
Net loss			(1,352,824)	(1,352,824)
Balance at Dec. 31, 2018	$ 10,037	6,842,465	(11,810,534)	(4,958,032)
Balance, shares at Dec. 31, 2018	10,036,505
Balance at Sep. 30, 2018	$ 9,657	6,052,161	(10,457,710)	(4,395,892)
Balance, shares at Sep. 30, 2018	9,656,505
Balance at Mar. 31, 2019	$ 12,945	14,454,110	(14,022,424)	444,631
Balance, shares at Mar. 31, 2019	12,944,514
Balance at Dec. 31, 2018	$ 10,037	6,842,465	(11,810,534)	(4,958,032)
Balance, shares at Dec. 31, 2018	10,036,505
Issuance of common stock under private placement	$ 1,744	3,164,640		3,166,384
Issuance of common stock under private placements, shares	1,743,979
Issuance of warrants under private placements		1,193,564		1,193,564
Issuance costs related to private placements		(698,777)		(698,777)
Issuance of common stock upon conversion of convertible promissory notes	$ 839	1,920,881		1,921,720
Issuance of common stock upon conversion of convertible promissory notes, shares	839,179
Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes		1,921,720		1,921,720
Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes, shares
Share-based compensation - employee		30,085		30,085
Share-based compensation - non-employee		16,569		16,569
Exercise of stock options	$ 94	3,179		3,273
Exercise of stock options, shares	93,555
Exercise of warrants	$ 231	416,102	(14,022,424)	416,333
Exercise of warrants, shares	231,296
Net loss			(2,211,890)	(2,211,890)
Balance at Mar. 31, 2019	$ 12,945	14,454,110	(14,022,424)	444,631
Balance, shares at Mar. 31, 2019	12,944,514
Balance at Sep. 30, 2019	$ 13,494	15,987,799	(17,238,871)	(1,237,578)
Balance, shares at Sep. 30, 2019	13,493,705
Issuance of common stock under securities purchase agreement	$ 142	254,858		255,000
Issuance of common stock under securities purchase agreement, shares	141,666
Issuance of warrants in connection with convertible notes offering		419,635		419,635
Stock-based compensation		463,084		463,084
Issuance of common stock for consulting services	$ 90	124,503		124,593
Issuance of common stock for consulting services, shares	90,000
Issuance of common stock upon vesting of restricted stock units	$ 11	(11)
Issuance of common stock upon vesting of restricted stock units, shares	10,503
Net loss			(4,637,066)	(4,637,066)
Balance at Dec. 31, 2019	$ 13,737	17,249,868	(21,875,937)	(4,612,332)
Balance, shares at Dec. 31, 2019	13,735,874
Stock-based compensation		88,806		88,806
Issuance of common stock upon conversion of convertible promissory notes	$ 61	239,461		239,522
Issuance of common stock upon conversion of convertible promissory notes, shares	60,847
Exercise of stock options	$ 42	1,446		1,488
Exercise of stock options, shares	42,525
Issuance of common stock for consulting services	$ 61	153,520		153,581
Issuance of common stock for consulting services, shares	61,000
Issuance of common stock upon vesting of restricted stock units	$ 122	289,272		289,394
Issuance of common stock upon vesting of restricted stock units, shares	122,177
Net loss			(1,345,642)	(1,345,642)
Balance at Mar. 31, 2020	$ 14,023	$ 18,022,373	$ (23,221,579)	$ (5,185,183)
Balance, shares at Mar. 31, 2020	14,022,423

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (5,982,708)	$ (3,564,714)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	20,965	10,622
Stock-based compensation	1,119,458	189,197
Non-cash interest on convertible notes	1,831,940	51,333
Non-cash discount amortization on convertible notes		233,224
Revaluation of convertible notes	93,858
Revaluation of premium conversion derivatives and warrant liability		129,763
Issuance costs attributed to financing activities	865,567
Loss on notes extinguishment		553,447
Lease liability principal payment deferral	4,038
Right-of-use asset depreciation adjustment	(4,038)
Change in assets and liabilities:
Prepaid and other assets	(40,303)	(74,574)
Accounts payable and other accrued liabilities	(383,855)	(104,578)
Net cash used in operating activities	(2,475,078)	(2,576,280)
Investing activities
Purchase of fixed assets and intangible assets	(40,224)	(65,000)
Net cash used in investing activities	(40,224)	(65,000)
Financing activities
Proceeds from issuance of convertible promissory notes	3,234,800
Issuance costs related to convertible notes	(417,176)
Proceeds from unsecured loans		245,000
Proceeds from issuance of common stock in connection with private placements	255,000	3,768,032
Proceeds from issuance of warrants in connection with private placements		1,416,915
Exercise of warrants		416,333
Exercise of stock options	1,488	3,273
Repayment of unsecured loans		(299,000)
Issuance costs related to private placements	(72,315)	(617,134)
Net cash provided by financing activities	3,001,797	4,933,419
Net increase in cash	486,495	2,292,139
Cash at beginning of period	260,749	13,260
Cash at end of period	747,244	2,305,399
Supplemental non-cash financing and investing transactions:
Conversion of convertible promissory notes to equity		1,678,361
Exercise of premium conversion derivative liability		419,590
Reclassification of warrant liability to equity		835,723
Unpaid issuance costs attributed to convertible notes and private placement	28,756	230,959
Broker warrants issued in connection with convertible notes	419,635
Purchased fixed assets in accounts payable and accrued expenses	2,500
Operating lease right of use asset obtained in exchange for operating lease	$ 335,119

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	NOTE 1 – Description of Business and Basis of Presentation NeuroOne Medical Technologies Corporation (the "Company"), a Delaware Corporation, is an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson's disease, essential tremors, and other brain related disorders. To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology. The Company received clearance to market the initial device and expect to submit for additional clearance for a second product by end of year. The Company is also evaluating different options for commercializing the current approved device. The Company is based in Eden Prairie, Minnesota. COVID-19 On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus ("COVID-19") as a global pandemic, which continues to spread throughout the United States and around the world. As a result of the COVID-19 pandemic, the Company has experienced delays and disruptions in its pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, and research and development operations. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic may impact our business and pre-clinical and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic may also impact the Company's ability to secure additional financing or its ability to up-list from its current OTC Market ("OTCQB"), and may result in further modifications to its debt agreements. See NOTE 12 – Subsequent Events. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company's results of future operations, financial position, and liquidity in fiscal year 2020. Basis of presentation The accompanying condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended September 30, 2019 included in the Annual Report on Form 10-K. The condensed balance sheet at September 30, 2019 was derived from the audited financial statements of the Company. In December 2019, the Company merged its wholly owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the Company's wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company did not have any remaining entities that required consolidation for financial statement reporting purposes. In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2020
Going Concern [Abstract]
Going Concern	NOTE 2 – Going Concern The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and has negative working capital, negative cash flows from operations, and an accumulated deficit of $23,221,579 as of March 31, 2020. The Company has not established a source of revenues to cover its operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology. The Company does not have adequate liquidity to fund its operations without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, these actions are not solely within the control of the Company. If the Company is unable to raise additional funds, or the Company's anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company's operations. If management is unable to obtain the necessary capital, it may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – Summary of Significant Accounting Policies Management’s Use of Estimates The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company’s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2020, the Company did have deposits in excess of federally insured amounts by $497,244. Common Stock Valuation The Company has been utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company’s common stock since September 30, 2019. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the “AICPA Valuation Framework”). The valuation methodology included estimates and assumptions that required the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates. The fair value the Company’s common stock is used as an input into the fair value determination of instruments recorded at fair value and stock option or other equity awards that the Company has issued. Fair Value of Financial Instruments The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of March 31, 2020 and September 30, 2019, the fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the convertible notes outstanding during the three and six month period ended March 31, 2020 were based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs. The estimated fair value of the convertible promissory notes of the Company that were outstanding during the three and six month period ended March 31, 2019 were based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes outstanding during fiscal 2019 were based on both the estimated fair value of our common stock and cash flow models discounted at the then current implied market rates evidenced in arms-length transactions representing expected returns by market participants for similar instruments during that period and were based on Level 3 inputs. There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019. The fair value of financial instruments measured on a recurring basis is as follows: As of March 31, 2020 Description Total Level 1 Level 2 Level 3 Liabilities: Convertible Notes $ 4,921,076 — — $ 4,921,076 Total liabilities at fair value $ 4,921,076 — — $ 4,921,076 The following table provides a roll-forward of the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the six month periods ended March 31 as follows: 2020 Convertible notes Balance as of beginning of period – September 30, 2019 $ — Fair value attributed to convertible promissory notes upon issuance 5,066,740 Conversion of convertible promissory notes to common stock (239,522 ) Change in fair value including accrued interest 93,858 Balance as of end of period – March 31, 2020 $ 4,921,076 2019 Warrant liability Balance as of beginning of period – September 30, 2018 $ 817,155 Change in fair value of warrant liability 18,568 Reclassification to equity upon conversion of convertible promissory notes (835,723 ) Balance as of end of period – March 31, 2019 $ — 2019 Premium debt conversion derivatives Balance as of beginning of period – September 30, 2018 $ 308,395 Change in fair value of premium debt conversion derivatives 111,195 Reclassification to equity upon conversion of convertible promissory notes (419,590 ) Balance as of end of period – March 31, 2019 $ — Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology. Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred. Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Debt Issuance Costs Debt issuance costs are recorded as a reduction of the convertible promissory notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed statements of operations. Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (ASC) 730, Research and Development Warrant Liability The Company issued warrants to purchase equity securities in connection with the issuance or amendment of the convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders’ (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the condensed statements of operations. Premium Debt Conversion Derivatives The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of operations based on the fair value of its common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs. Income Taxes For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Net Loss Per Share For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s convertible promissory notes, warrants, stock options and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and six month periods ended March 31, 2020 and 2019. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and six month periods ended March 31, 2020 and 2019: 2020 2019 Warrants 8,389,987 6,448,613 Stock options 1,355,512 600,209 Restricted stock units 59,090 — Convertible notes 1,648,287 — Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company adopted the new standard on October 1, 2019 and did not have a material impact on the Company’s statements of comprehensive loss or statements of cash flows for agreements in place as of the adoption date. As such, the Company did not restate comparative periods and did not recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company elected the short-term lease expedient upon adoption of the standard. See NOTE 4 – Commitments and Contingencies with regard to a new operating lease that commenced after the adoption date on November 1, 2019. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement . ● Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ● Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. ● Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance and does not expect that it will have a material impact on its financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial statements.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 4 – Commitments and Contingencies WARF License amendment The Company entered into an Amended and Restated Exclusive Start-up Company License Agreement (the "WARF License") with Wisconsin Alumni Research Foundation ("WARF") on January 21, 2020, which amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1, 2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019. The WARF License grants to the Company an exclusive license to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. The Company has agreed to pay WARF a royalty equal to a single-digit percentage of its product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. If the Company or any of its sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by the Company if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License. WARF may terminate the WARF License if the Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, or breaches any other covenant in the WARF License and fails to remedy such default in ninety (90) days or in the event of certain bankruptcy events involving the Company. WARF may also terminate the WARF License on ninety (90) days' notice if the Company fails to have commercial sales of one or more FDA-approved products under the WARF License by June 30, 2020. The WARF License otherwise expires by its terms (i) on the date that no valid claims on the patents licensed thereunder remain or (ii) upon the cessation for more than four (4) calendar quarters of the payment, once begun, of earned royalties under certain sections of the WARF License. The Company expects the latest expiration of a licensed patent to occur in 2030. In addition, WARF reserves the right to grant non-profit research institutions and government agencies non-exclusive licenses to practice and use the inventions of the licensed patents for non-commercial research purposes, and the Company grants WARF a non-exclusive, sub licensable, royalty-free right and license for non-commercial research purposes to use improvements to the licensed patents. In the event that the Company discontinues use or commercialization of the licensed patents or improvements thereon, the Company must grant WARF an option to obtain a non-exclusive, sub-licensable royalty-bearing license to use the improvements for commercial purposes. Legal From time to time, the Company is subject to litigation and claims arising in the ordinary course of business. In May 2017, NeuroOne received a letter from PMT Corporation ("PMT"), the former employer of Mark Christianson and Wade Fredrickson. PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer's prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with contracts. The letter, which purported to attach a noncompete agreement signed by Mr. Fredrickson, demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne's systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer. On March 29, 2018, the Company was served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. The complaint purported to attach Mr. Fredrickson's noncompete agreement as Exhibit A. In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT's contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition. PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys' fees, costs and interest. On April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal states that: the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff's claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition. On January 7, 2019, the judge granted the motion for dismissal with respect to PMT's claim for breach of the duty of good faith and fair dealing, and denied the motion for dismissal with respect to the other claims presented. In April 2019, PMT served the Company, NeuroOne, Inc and Christianson with a proposed Second Amended Complaint, which included new claims against the Company and NeuroOne, Inc for tortious interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne Inc. and Christianson. On June 28, 2019 the Company presented evidence indicating that PMT had participated in a fraud on the Court and sought an Order that PMT had waived the attorney client privilege. On July 16, 2019, the defendants served PMT with a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal of the case and an award of attorneys' fees. The Company, NeuroOne Inc and Mr. Christianson further intend to move for summary judgment on all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process. On August 30, 2019, the Hennepin County District Court heard dispositive motions in this case. The district court judge indicated some claims would likely be tried to a jury and encouraged the parties to settle. On September 12, 2019 the district court heard NeuroOne's motion for sanctions. The district court held the sanctions hearing on December 17, 2019 and December 18, 2019 and indicated that a ruling would be made in approximately 90 days. NeuroOne and Mark Christianson (who has not worked for PMT since February 2012) intend to continue to defend themselves vigorously. The Court issued multiple rulings on the Company's request for summary judgment and sanctions against PMT in April 2020. See NOTE 12 – Subsequent Events. Facility Lease On October 7, 2019, the Company entered into a non-cancellable lease agreement (the "Lease") with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the "Landlord") pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the "Premises"). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the "Term"). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord's annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months. Prior to the October 2019 Lease, the Company entered into a non-cancellable facility lease for its operations and headquarters for an eleven month term beginning on December 1, 2018. The monthly rent under that lease was $4,763. During the three month periods ended March 31, 2020 and 2019, rent expense associated with the facility leases amounted to $25,862 and $14,289, respectively, and $47,866 and $19,052 during the six month periods ended March 31, 2020 and 2019, respectively. Supplemental cash flow information related to the operating lease was as follows: Six months March 31, Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating leases $ — Right-of -use assets obtained in exchange for lease obligations: Operating leases $ 335,119 Supplemental balance sheet information related to the operating lease was as follows: As of March 31, Right-of-use assets $ 308,055 Lease liability $ 339,157 Weighted average remaining lease term (years) 5.0 Weighted average discount rate 7.0 % Maturity of the lease liability was as follows: As of March 31, 2020 2020 (period from April 1, 2020 to September 30, 2020) $ 38,462 2021 77,884 2022 79,832 2023 81,827 2024 83,873 2025 42,454 Total lease payments 404,332 Less imputed interest (65,175 ) Total 339,157 Short-term portion (54,922 ) Long-term portion $ 284,235

Intangibles and Property and Eq

Intangibles and Property and Equipment	6 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles and Property and Equipment	NOTE 5 – Intangibles and Property and Equipment Intangibles Intangible assets rollforward is as follows: Useful Life Net Intangibles, September 30, 2019 12-13 years $ 178,838 Less: amortization (11,158 ) Net Intangibles, March 31, 2020 $ 167,680 Amortization expense was $5,579 and $5,311 for the three months ended March 31, 2020 and 2019, respectively, and 11,158 and $10,622 for the six months ended March 31, 2020 and 2019, respectively. Property and Equipment Property and equipment held for use by category are presented in the following table: As of March 31, September 30, Equipment and furniture $ 99,181 $ 56,457 Software 1,895 1,895 Total property and equipment 101,076 58,352 Less accumulated depreciation (16,133 ) (6,326 ) Property and equipment, net $ 84,943 $ 52,026 Depreciation expense was $5,488 and zero for the three months ended March 31, 2020 and 2019, respectively, and $9,807 and zero for the six months ended March 31, 2020 and 2019, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	NOTE 6 - Accrued Expenses Accrued expenses consisted of the following at March 31, 2020 and September 30, 2019: As of March 31, September 30, Legal services $ — $ 228,709 Accrued issuance costs 50,400 50,400 Accrued payroll 126,001 171,087 Lease liability, short-term 54,922 — Other 60,551 167,525 $ 291,874 $ 617,721 The “other” category is primarily comprised of board fees.

Convertible Promissory Notes an

Convertible Promissory Notes and Warrant Agreements	6 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Promissory Notes and Warrant Agreements	NOTE 7 – Convertible Promissory Notes and Warrant Agreements As of As of Paulson convertible notes, principal $ 3,085,200 $ — Accrued interest 152,036 — Fair value adjustments 1,683,840 — $ 4,921,076 $ — Paulson Convertible Note Offering On November 1, 2019, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the “2019 Paulson Private Placement”), agreed to issue and sell to the investors 13% convertible promissory notes (each, a “2019 Paulson Note” and collectively, the “2019 Paulson Notes”) and warrants (each, a “2019 Paulson Warrant” and collectively, the “2019 Paulson Warrants”) to purchase shares of the Company’s common stock. The initial closing of the 2019 Paulson Private Placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued the 2019 Paulson Notes in an aggregate principal amount of $3,234,800 to the subscribers for gross proceeds equaling the principal amount. The 2019 Paulson Private Placement terminated on December 3, 2019. The 2019 Paulson Notes bear interest at a fixed rate of 13% per annum and originally required the Company to repay the principal and accrued and unpaid interest thereon on May 1, 2020. The 2019 Paulson Notes were amended in April 2020 to extend the maturity date to November 1, 2020. See NOTE 12 – Subsequent Events for amended terms under the 2019 Paulson Notes. Interest on principal amounted to $100,269 and $154,144 during the three and six month periods ended March 31, 2020, respectively, and was recorded under the net valuation change of instruments measured at fair value in the condensed statements of operations. The subscriber has the option to convert the outstanding principal and accrued and unpaid interest of such subscriber’s 2019 Paulson Note (the “Outstanding Balance”) into common stock in an amount equal to the Outstanding Balance divided by the ten day volume weighted average closing price (“VWAP”) of the common stock prior to conversion. In addition, if the Company raises more than $3,000,000 in an equity financing (the “2019 Qualified Financing”) before the maturity date, each subscriber shall have the option to convert the Outstanding Balance into the securities issued by the Company in such 2019 Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the 2019 Qualified Financing or (B) the ten day VWAP of the common stock prior to the first closing of a 2019 Qualified Financing. If a change of control transaction occurs prior to a 2019 Qualified Financing or the maturity date, the 2019 Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company’s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company’s assets. The Company elected to account for the 2019 Paulson Notes on a fair value basis under ASC 825 to comprehensively value and streamline the accounting for the embedded conversion options Each 2019 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2019 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. As of the final closing on December 3, 2019, the Company issued 2019 Paulson Warrants exercisable for 864,913 shares of common stock in connection with all closings of the 2019 Paulson Private Placement. The 2019 Paulson Warrants are immediately exercisable and expire on November 1, 2022. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein. The 2019 Paulson warrants were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2019 Paulson Notes exceeded the proceeds received at issuance, there was no value attributed to the 2019 Paulson Warrants in the condensed financial statements. In connection with the 2019 Private Placement, Paulson Investment Company, LLC (“Paulson”) received a cash commission equal to 12% of the gross proceeds from the sale of the 2019 Paulson Notes, and 10-year warrants to purchase an amount of Common Stock equal to 259,476 shares of common stock at an exercise price equal to $1.87 per share (the “Broker Warrants”). The issuance costs incurred during the six months ended March 31, 2020 in connection with the 2019 Paulson Private Placement were $865,567. Issuance costs included cash commissions equal to $388,176 and legal and third party fees in the amount of $57,756. In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. There were no issuance costs incurred in connection with 2019 Paulson Notes during the three months ended March 31, 2020. The issuance costs were recorded as a component of interest in the accompanying condensed statements of operations. During the six months ended March 31, 2020, 2019 Paulson Notes with a fair value of $239,522 were converted into 60,847 shares of common stock. 2017 Convertible Notes From October 2017 to May 2018, the Company issued convertible notes (the “2017 Convertible Notes”) in an aggregate principal amount of $1,540,000 that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company’s capital stock (the “2017 Warrants”). On February 28, 2019, the 2017 Convertible Notes were converted into 839,179 shares of common stock and 839,179 common stock purchase warrants with an exercise term of approximately 4.8 years and an exercise price $3.00 per share. In addition, the previously issued 2017 Warrants became immediately exercisable for 839,179 shares of common stock. The conversion was accounted for as a debt extinguishment given the bifurcation of the embedded premium debt conversion feature. The fair value of the newly issued common shares and warrants associated with the 2017 Convertible Notes conversion relative to the carrying value of the debt and fair value of warrant liability and premium derivative liability on the conversion date was $553,447 and was recorded as a loss on note extinguishment in the accompanying condensed statements of operations for the three and six months ended March 31, 2019. During the three and six month periods ended March 31, 2019, interest on the principal was $20,534 and $51,333, respectively, and interest related to amortization of discounts related to the bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amounted to zero and $233,224, respectively. The fair value changes related to the underlying premium conversion derivative and warrant liability amounted to an expense of $116,809 and $129,763 during the three and six month periods ended March 31, 2019, respectively. As noted above, the 2017 Convertible Notes were converted into shares of common stock and not outstanding during the three and six month periods ended March 31, 2020.

Defined Contribution Plan

Defined Contribution Plan	6 Months Ended
	Mar. 31, 2020
Retirement Benefits [Abstract]
Defined Contribution Plan	NOTE 8 – Defined Contribution Plan The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through March 31, 2020. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee’s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee’s date of hire. No matching contributions were made during the three and six month periods ended March 31, 2020. During the six month period ended March 31, 2019, there was a benefit reduction adjustment of $(4,359) given an overpayment. There were no matching contributions during the three month period ended March 31, 2019.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	NOTE 9 – Stock-Based Compensation Stock-based compensation expense was included in general and administrative and research and development expenses as follows in the accompanying condensed statements of operations: Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019 General and administrative $ 495,690 $ 26,105 $ 1,059,458 $ 141,105 Research and development 36,091 44,112 60,000 48,092 Total share-based compensation $ 531,781 $ 70,217 $ 1,119,458 $ 189,197 Stock Options During the three month period ended March 31, 2020 and 2019, under the 2017 Equity Incentive Plan (the “2017 Plan”), the Company granted 20,000 and 150,548 stock options, respectively, to its employees, consultants and scientific advisory board members. During the six month periods ended March 31, 2020 and 2019, under the 2017 Plan, the Company granted 820,000 and 325,548 stock options, respectively, to its employees, consultants and scientific advisory board members. Vesting generally occurs over an immediate to 48 month period based on a time of service condition although vesting acceleration is provided under one grant in the event that certain milestones are met. The grant date fair value of the grants issued during the three month periods ended March 31, 2020 and 2019 was $1.15 and $1.11 per share, respectively. The grant date fair value of the grants issued during the six month periods ended March 31, 2020 and 2019 was $1.06 and $1.12 per share, respectively. The total expense for the three months ended March 31, 2020 and 2019 related to stock options was $88,806 and $46,654, respectively. The total expense for the six month periods ended March 31, 2020 and 2019 related to stock options was $526,888 and $46,654, respectively. The total number of stock options outstanding as of March 31, 2020 and September 30, 2019 was 1,355,512 and 845,840, respectively. The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and six month periods ended March 31, 2020 and 2019: Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019 Expected stock price volatility 54.3 % 50.7 % 52.8 % 50.2 % Expected life of options (years) 5.4 6.0 5.7 5.9 Expected dividend yield 0 % 0 % 0 % 0 % Risk free interest rate 1.4 % 2.6 % 1.7 % 2.7 % During the three and six month periods ended March 31, 2020, 46,865 and 422,694 stock options vested, respectively, and 39,675 stock options vested during the three and six months ended March 31, 2019. During the three and six month periods ended March 31, 2020, 260,306 and 267,803 stock options were forfeited, respectively, and no options were forfeited during the three and six month periods ended March 31, 2019. Restricted Stock Units During the three and six month periods ended March 31, 2020, 167,851 restricted stock units (“RSUs”) were granted. During the three and six month periods ended March 31, 2019, no RSUs were granted. During the three and six month periods ended March 31, 2020, 122,767 and 133,272 RSUs vested, respectively. No RSUs vested during the three and six month periods ended March 31, 2019. The total expense for the three and six month period ended March 31, 2020 related to the RSU’s was $289,394 and $314,395, respectively. No expense was recognized related to the RSUs during the three and six month periods ended March 31, 2019. The number of RSUs forfeited during the three and six month periods ended March 31, 2020 was zero and 7,003, respectively. No RSUs were forfeited during the three and six month periods ended March 31, 2019. Other Stock-Based Awards In October 2019, two consulting agreements were executed whereby up to 115,000 shares of common stock were issuable of which 90,000 shares of common stock were issued and vested as of March 31, 2020 under these agreements. Vesting is based on a time-based vesting condition ranging over a three to nine month period commencing upon the execution of the consulting agreements. In February 2020, an additional consulting agreement was executed whereby up to 90,000 shares of common stock were issuable of which 36,000 shares of common stock were issued and vested as of March 31, 2020 under this agreement. Compensation expense related to the stock awards granted under these consulting agreements amounted to $153,581 and $278,175 and was included in the total stock-based expense referenced above for the three and six month periods ended March 31, 2020, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which ranged from $2.00 to $2.65 per share. In February 2018, 250,000 shares of common stock were reserved as a result of a consulting agreement for investor relations services executed in February 2018. Under the agreement, zero and 50,000 shares of common stock were awarded during the three and six month period ended March 31, 2019, respectively, on a time-based vesting condition that was met in November 2018. The compensation expense related to the vested common shares was included in the total stock-based expense referenced above which totaled zero and $115,000 for the three and six month periods ended March 31, 2019, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which was $2.30 per share. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. As of March 31, 2019, the Company had formal obligation to issue future common stock options relating to several consulting agreements. The corresponding stock-based compensation expense related to the stock-based award liabilities amounted to $23,563 and $27,543 during the three and six month periods ended March 31, 2019, respectively, and was included in general and administrative expense in the accompanying condensed statements of operations. General As of March 31, 2020, 2,063,506 shares were available for future issuance on a combined basis under the 2016 Equity Incentive Plan and 2017 Plan. Unrecognized stock-based compensation was $0.8 million as of March 31, 2020. The unrecognized share-based expense is expected to be recognized over a weighted average period of 2.9 years.

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 – Income Taxes The effective tax rate for the three and six months ended March 31, 2020 and 2019 was zero percent. As a result of the analysis of all available evidence as of March 31, 2020 and September 30, 2019, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported no income tax benefit during the three and six months ended March 31, 2020 and 2019. If the Company's assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense. If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets. However, the Company is continuing to assess the impact of the CARES Act. On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") which includes modifications to the limitation on business interest expense and net operating loss provisions, and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act is not expected to have a material impact on the Company's financial statements.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Mar. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	NOTE 11 – Stockholders’ Deficit Common Stock Offering On October 23, 2019, the Company entered into Securities Purchase Agreements with certain accredited investors, pursuant to which the Company, in a private placement, has issued and sold 141,666 shares of the Company’s common stock to the accredited investors at a price of $1.80 per share, for gross proceeds amounting to $255,000. In connection with the private placement, the Company has agreed to issue and sell to accredited investors up to a maximum of 555,555 shares for total gross proceeds to the Company of up to $1,000,000. The Company intends to use the net proceeds from this private placement for funding operations or working capital and general corporate purposes. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the private placement within 60 days of the termination of the private placement. 2019 Private Placement From December 28, 2018 through July 1, 2019, the Company entered into Subscription Agreements (each, a “2019 Purchase Agreement”) with certain accredited investors (the “New Purchasers”), pursuant to which the Company, in a new private placement (the “2019 Unit Private Placement”), agreed to issue and sell Units (the “2019 Units”), each consisting of (i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”), to the New Purchasers. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Unit Private Placement. The initial closing of the 2019 Unit Private Placement was consummated on December 28, 2018. The Company issued and sold an aggregate of 2,338,179 of the 2019 Units at $2.50 per Unit to the New Purchasers, for total gross proceeds to the Company of approximately $5,845,448 before deducting offering expenses (1,743,979 and 1,903,979 of the 2019 Units were sold during the three and six month periods ended March 31, 2019, respectively). In connection with the 2019 Unit Private Placement, the Company recorded issuance costs in the amount of $1,150,359 ($722,806 and $812,428 recorded during the three and six month periods ended March 31, 2019, respectively). The 2019 Unit Private Placement was terminated on July 1, 2019. 2018 Private Placement From July 9, 2018 through November 30, 2018 (the final closing), the Company entered into subscription agreements (each, a “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company, in a private placement (the “2018 Private Placement”), agreed to issue and sell to the Purchasers units (each, a “2018 Unit”), each consisting of (i) 1 share (each, a “Share”) of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”). The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying condensed balance sheets based on their relative fair value to the underlying common shares issued. The initial closing of the 2018 Private Placement was consummated on July 9, 2018 and was terminated on December 12, 2018. As of the termination of the 2018 Private Placement on December 12, 2018, the Company had issued and sold an aggregate of 615,200 of the 2018 Units at a price of $2.50 per Unit to the Purchasers, for total gross proceeds to the Company of $1,538,000 before deducting offering expenses (zero and 170,000 of the 2018 Units were sold during the three and six month periods ended March 31, 2019, respectively). In connection with the 2018 Private Placement, the Company recorded issuance costs in the amount of $173,067 (a reduction adjustment of $(24,029) and a cost of $35,665 recorded during the three and six month periods ended March 31, 2019, respectively). Warrant Activity and Summary The following table summarizes warrant activity during the six month period ended March 31, 2020: Exercise Weighted Weighted Warrants Per Warrant Exercise Price Term (years) Outstanding and exercisable at September 30, 2019 7,265,598 $ 1.80 - 3.00 $ 2.55 3.60 Issued 1,124,389 $ 1.87 $ 1.87 4.26 Exercised — $ — $ — — Forfeited — $ — $ — — Outstanding and exercisable at March 31, 2020 8,389,987 $ 1.80 - 3.00 $ 2.45 3.26

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12 – Subsequent Events Amendment of 2019 Paulson Notes On April 24, 2020, the Company and holders of a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the "Second Paulson Amendment") to, among other things: i. Extend the Maturity Date – ii. Revise Optional Conversion Terms – iii. Revise the Registration Date – There were no other significant changes to terms under the Second Paulson Amendment. 2019 Paulson Note Conversion Between April 24, 2020 and May 1, 2020, certain holders elected to convert outstanding principal and accrued and unpaid interest of 2019 Paulson Notes in the amount of $2,633,280 into 2,054,245 shares of common stock. Paulson 2020 Convertible Note Financing On April 30, 2020, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the "2020 Paulson Private Placement"), agreed to issue and sell to the investors up to $3 million of 13% convertible promissory notes (each, a "2020 Paulson Note" and collectively, the "2020 Paulson Notes") and warrants (each, a "2020 Paulson Warrant" and collectively, the "2020 Paulson Warrants") to purchase shares of the Company's common stock. Between April 30, 2020 and May 8, 2020, the Company issued 2020 Paulson Notes in an aggregate principal amount of $2,469,800 to the Subscribers. The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $6,000,000 or a higher amount determined by the Board. The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the "2020 Qualified Financing"), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the "Outstanding Balance") shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing. If the Company announces a transaction between the Company and any other company (or an affiliate of any such company) that is included in the S&P 500 Health Care Index as published from time to time by S&P Dow Jones Indices LLC that includes an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration, manufacturing, distribution, licensing or supply of the Company's products (a "Strategic Transaction") before the maturity date, without any action on the part of the subscribers, the Outstanding Balance shall be converted into that number of shares of common stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the Company of a Strategic Transaction. At any time, at the sole election of the holder of such 2020 Paulson Note, all or a portion of the Outstanding Balance may be converted into that number of shares of common stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion. If a change of control transaction occurs prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets. Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction. In connection with the 2020 Paulson Private Placement, Paulson will receive a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes, and at the final closing of the 2020 Paulson Private Placement, Paulson will receive 7-year warrants to purchase an amount of common stock equal to 15% of the total gross proceeds received by the Company in the 2020 Paulson Private Placement, divided by 1.87 (the "Broker Warrants"). The Broker Warrants will have an exercise price equal to $1.87. 2020 Paulson Note Conversions Between May 4, 2020 and May 12, 2020, certain Subscribers elected to convert $50,153 of the outstanding principal and interest of such Subscribers' 2020 Paulson Notes into 38,335 shares of common stock. Payroll Protection Program The CARES Act, signed into law in March 2020, established the Paycheck Protection Program ("PPP"). The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments may be made without penalty. In April 2020, the Company received loan funding of approximately $83,333 under the PPP. Amendment to Veritas Consulting Agreement On April 22, 2020, the Company entered into an amendment (the "Amendment") to the Consulting Agreement, by and between the Company and Veritas Consulting Group Inc. ("Veritas"). Pursuant to the Amendment, the Company issued Veritas an additional 35,000 shares in exchange for consulting services. PMT Litigation On April 29, 2020, the district court granted the Company's motion for sanctions. Additionally, the district court granted the Company's motion for summary judgment in part with respect to the counts for Christianson's breach of non-confidentiality agreement, Fredrickson's breach of confidentiality covenants, and the creation of a constructive trust and denied the Company's motion for summary judgment on all other counts.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Management's Use of Estimates	Management's Use of Estimates The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company's cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2020, the Company did have deposits in excess of federally insured amounts by $497,244.
Common Stock Valuation	Common Stock Valuation The Company has been utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company's common stock since September 30, 2019. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants' Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the "AICPA Valuation Framework"). The valuation methodology included estimates and assumptions that required the Company's judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates. The fair value the Company's common stock is used as an input into the fair value determination of instruments recorded at fair value and stock option or other equity awards that the Company has issued.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of March 31, 2020 and September 30, 2019, the fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the convertible notes outstanding during the three and six month period ended March 31, 2020 were based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs. The estimated fair value of the convertible promissory notes of the Company that were outstanding during the three and six month period ended March 31, 2019 were based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes outstanding during fiscal 2019 were based on both the estimated fair value of our common stock and cash flow models discounted at the then current implied market rates evidenced in arms-length transactions representing expected returns by market participants for similar instruments during that period and were based on Level 3 inputs. There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019. The fair value of financial instruments measured on a recurring basis is as follows: As of March 31, 2020 Description Total Level 1 Level 2 Level 3 Liabilities: Convertible Notes $ 4,921,076 — — $ 4,921,076 Total liabilities at fair value $ 4,921,076 — — $ 4,921,076 The following table provides a roll-forward of the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the six month periods ended March 31 as follows: 2020 Convertible notes Balance as of beginning of period – September 30, 2019 $ — Fair value attributed to convertible promissory notes upon issuance 5,066,740 Conversion of convertible promissory notes to common stock (239,522 ) Change in fair value including accrued interest 93,858 Balance as of end of period – March 31, 2020 $ 4,921,076 2019 Warrant liability Balance as of beginning of period – September 30, 2018 $ 817,155 Change in fair value of warrant liability 18,568 Reclassification to equity upon conversion of convertible promissory notes (835,723 ) Balance as of end of period – March 31, 2019 $ — 2019 Premium debt conversion derivatives Balance as of beginning of period – September 30, 2018 $ 308,395 Change in fair value of premium debt conversion derivatives 111,195 Reclassification to equity upon conversion of convertible promissory notes (419,590 ) Balance as of end of period – March 31, 2019 $ —
Intellectual Property	Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are recorded as a reduction of the convertible promissory notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed statements of operations.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (ASC) 730, Research and Development
Warrant Liability	Warrant Liability The Company issued warrants to purchase equity securities in connection with the issuance or amendment of the convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders' (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the condensed statements of operations.
Premium Debt Conversion Derivatives	Premium Debt Conversion Derivatives The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of operations.
Income Taxes	Income Taxes For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Net Loss Per Share	Net Loss Per Share For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's convertible promissory notes, warrants, stock options and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and six month periods ended March 31, 2020 and 2019. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and six month periods ended March 31, 2020 and 2019: 2020 2019 Warrants 8,389,987 6,448,613 Stock options 1,355,512 600,209 Restricted stock units 59,090 — Convertible notes 1,648,287 —
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company adopted the new standard on October 1, 2019 and did not have a material impact on the Company’s statements of comprehensive loss or statements of cash flows for agreements in place as of the adoption date. As such, the Company did not restate comparative periods and did not recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company elected the short-term lease expedient upon adoption of the standard. See NOTE 4 – Commitments and Contingencies with regard to a new operating lease that commenced after the adoption date on November 1, 2019. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement . ● Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ● Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. ● Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance and does not expect that it will have a material impact on its financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedule of fair value of financial instruments measured on a recurring basis	As of March 31, 2020 Description Total Level 1 Level 2 Level 3 Liabilities: Convertible Notes $ 4,921,076 — — $ 4,921,076 Total liabilities at fair value $ 4,921,076 — — $ 4,921,076
Schedule of convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis	2020 Convertible notes Balance as of beginning of period – September 30, 2019 $ — Fair value attributed to convertible promissory notes upon issuance 5,066,740 Conversion of convertible promissory notes to common stock (239,522 ) Change in fair value including accrued interest 93,858 Balance as of end of period – March 31, 2020 $ 4,921,076 2019 Warrant liability Balance as of beginning of period – September 30, 2018 $ 817,155 Change in fair value of warrant liability 18,568 Reclassification to equity upon conversion of convertible promissory notes (835,723 ) Balance as of end of period – March 31, 2019 $ — 2019 Premium debt conversion derivatives Balance as of beginning of period – September 30, 2018 $ 308,395 Change in fair value of premium debt conversion derivatives 111,195 Reclassification to equity upon conversion of convertible promissory notes (419,590 ) Balance as of end of period – March 31, 2019 $ —
Schedule of computation of diluted net loss per share	2020 2019 Warrants 8,389,987 6,448,613 Stock options 1,355,512 600,209 Restricted stock units 59,090 — Convertible notes 1,648,287 —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Summary of supplemental cash flow information related to the operating lease	Six months March 31, Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating leases $ — Right-of -use assets obtained in exchange for lease obligations: Operating leases $ 335,119
Summary of Supplemental balance sheet information related to the operating lease	As of March 31, Right-of-use assets $ 308,055 Lease liability $ 339,157 Weighted average remaining lease term (years) 5.0 Weighted average discount rate 7.0 %
Summary of Maturity of the lease liability	As of March 31, 2020 2020 (period from April 1, 2020 to September 30, 2020) $ 38,462 2021 77,884 2022 79,832 2023 81,827 2024 83,873 2025 42,454 Total lease payments 404,332 Less imputed interest (65,175 ) Total 339,157 Short-term portion (54,922 ) Long-term portion $ 284,235

Intangibles and Property and _2

Intangibles and Property and Equipment (Tables)	6 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Useful Life Net Intangibles, September 30, 2019 12-13 years $ 178,838 Less: amortization (11,158 ) Net Intangibles, March 31, 2020 $ 167,680
Schedule of property and equipment	As of March 31, September 30, Equipment and furniture $ 99,181 $ 56,457 Software 1,895 1,895 Total property and equipment 101,076 58,352 Less accumulated depreciation (16,133 ) (6,326 ) Property and equipment, net $ 84,943 $ 52,026

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of accrued expenses	As of March 31, September 30, Legal services $ — $ 228,709 Accrued issuance costs 50,400 50,400 Accrued payroll 126,001 171,087 Lease liability, short-term 54,922 — Other 60,551 167,525 $ 291,874 $ 617,721

Convertible Promissory Notes _2

Convertible Promissory Notes and Warrant Agreements (Tables)	6 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of convertible promissory notes and warrant agreements	As of As of Paulson convertible notes, principal $ 3,085,200 $ — Accrued interest 152,036 — Fair value adjustments 1,683,840 — $ 4,921,076 $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of share-based compensation expense	Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019 General and administrative $ 495,690 $ 26,105 $ 1,059,458 $ 141,105 Research and development 36,091 44,112 60,000 48,092 Total share-based compensation $ 531,781 $ 70,217 $ 1,119,458 $ 189,197
Schedule of weighted-average assumptions used black-scholes option-pricing model	Three Months Ended Six Months Ended March 31, March 31, 2020 2019 2020 2019 Expected stock price volatility 54.3 % 50.7 % 52.8 % 50.2 % Expected life of options (years) 5.4 6.0 5.7 5.9 Expected dividend yield 0 % 0 % 0 % 0 % Risk free interest rate 1.4 % 2.6 % 1.7 % 2.7 %

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Mar. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of warrant activity	Exercise Weighted Weighted Warrants Per Warrant Exercise Price Term (years) Outstanding and exercisable at September 30, 2019 7,265,598 $ 1.80 - 3.00 $ 2.55 3.60 Issued 1,124,389 $ 1.87 $ 1.87 4.26 Exercised — $ — $ — — Forfeited — $ — $ — — Outstanding and exercisable at March 31, 2020 8,389,987 $ 1.80 - 3.00 $ 2.45 3.26

Going Concern (Details)

Going Concern (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Going Concern (Textual)
Accumulated deficit	$ 23,221,579	$ 17,238,871

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	Mar. 31, 2020USD ($)
Liabilities:
Convertible Notes	$ 4,921,076
Total liabilities at fair value	4,921,076
Level 1 [Member]
Liabilities:
Convertible Notes
Total liabilities at fair value
Level 2 [Member]
Liabilities:
Convertible Notes
Total liabilities at fair value
Level 3 [Member]
Liabilities:
Convertible Notes	4,921,076
Total liabilities at fair value	$ 4,921,076

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - Convertible Notes [Member]	6 Months Ended
	Mar. 31, 2020USD ($)
Convertible notes
Balance as of beginning of period – September 30, 2019
Fair value attributed to convertible promissory notes upon issuance	5,066,740
Conversion of convertible promissory notes to common stock	(239,522)
Change in fair value including accrued interest	93,858
Balance as of end of period – March 31, 2020	$ 4,921,076

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reclassification to equity upon conversion of convertible promissory notes	$ 239,522	$ 1,921,720
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period – September 30, 2018			$ 817,155
Change in fair value of warrant liability			18,568
Reclassification to equity upon conversion of convertible promissory notes			(835,723)
Balance as of end of period – March 31, 2019

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reclassification to equity upon conversion of convertible promissory notes	$ 239,522	$ 1,921,720
Debt Conversion Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period – September 30, 2018			$ 308,395
Change in fair value of premium debt conversion derivatives			111,195
Reclassification to equity upon conversion of convertible promissory notes			(419,590)
Balance as of end of period – March 31, 2019

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details 4) - shares	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	8,389,987	6,448,613
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	1,355,512	600,209
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	59,090
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	1,648,287

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Mar. 31, 2020USD ($)Agreements
Summary of Significant Accounting Policies (Textual)
Deposits in excess of federally insured amounts | $	$ 497,244
Number of licencing agreements | Agreements	2
Equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	3 years
Equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	7 years
Software [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	3 years

Commitments and Contingencies_2

Commitments and Contingencies (Details)	6 Months Ended
	Mar. 31, 2020USD ($)
Cash paid for amounts included in the measurement of lease liability:
Operating cash flows from operating leases
Right-of -use assets obtained in exchange for lease obligations:
Operating leases	$ 335,119

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets	$ 308,055
Lease liability	$ 339,157
Weighted average remaining lease term (years)	5 years
Weighted average discount rate	7.00%

Commitments and Contingencies_4

Commitments and Contingencies (Details 2)	Mar. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020 (period from April 1, 2020 to September 30, 2020)	$ 38,462
2021	77,884
2022	79,832
2023	81,827
2024	83,873
2025	42,454
Total lease payments	404,332
Less imputed interest	(65,175)
Total	339,157
Short-term portion	(54,922)
Long-term portion	$ 284,235

Commitments and Contingencies_5

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Nov. 01, 2019
Commitments and Contingencies (Textual)
Royalty payments - 2020	$ 50,000		$ 50,000
Royalty payments - 2021	100,000		100,000
Royalty payments - 2022	150,000		150,000
Facility lease term					65 months
Monthly lease rent			$ 4,763
Lease rent expense,description			Prior to the October 2019 Lease, the Company entered into a non-cancellable facility lease for its operations and headquarters for an eleven month term beginning on December 1, 2018. The monthly rent under that lease was $4,763.
Facility lease agreement, description			On October 7, 2019, the Company entered into a non-cancellable lease agreement (the “Lease”) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the “Landlord”) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the “Term”). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.
Rent expense	$ 25,862	$ 14,289	$ 47,866	$ 19,052

Intangibles and Property and _3

Intangibles and Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Beginning Balance			$ 178,838
Less: amortization	$ (5,579)	$ (5,311)	(11,158)	$ (10,622)
Ending Balance	$ 167,680		$ 167,680
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life			12 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life			13 years

Intangibles and Property and _4

Intangibles and Property and Equipment (Details 1) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Equipment and furniture	$ 99,181	$ 56,457
Software	1,895	1,895
Total property and equipment	101,076	58,352
Less accumulated depreciation	(16,133)	(6,326)
Property and equipment, net	$ 84,943	$ 52,026

Intangibles and Property and _5

Intangibles and Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Intangibles and Property and Equipment (Textual)
Amortization expense	$ 5,579	$ 5,311	$ 11,158	$ 10,622
Depreciation expense	$ 5,488	$ 0	$ 9,807	$ 0

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Payables and Accruals [Abstract]
Legal services		$ 228,709
Accrued issuance costs	50,400	50,400
Accrued payroll	126,001	171,087
Lease liability, short-term	54,922
Other	60,551	167,525
Total accrued expenses	$ 291,874	$ 617,721

Convertible Promissory Notes _3

Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Short-term Debt [Line Items]
Accrued interest	$ 152,036
Fair value adjustments	1,683,840
Total	4,921,076
Paulson convertible notes, principal [Member]
Short-term Debt [Line Items]
Total	$ 3,085,200

Convertible Promissory Notes _4

Convertible Promissory Notes and Warrant Agreements (Details Textual) - USD ($)	Dec. 03, 2019	Feb. 28, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Nov. 01, 2019
Convertible Promissory Notes and Warrant Agreements (Textual)
Net valuation change of instruments measured at fair value			$ 31,716	$ (116,809)	$ (93,858)	$ (129,763)
Paulson Private Placement [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Issuance cost					419,635
Issuance cost include cash commission					388,176
Legal and third party fee					$ 57,756
Paulson Private Placement [Member] | Common Stock [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Warrants exercise price			$ 1.87		$ 1.87
Warrants to purchase of common stock shares					259,476
Exercise price, per share			$ 1.87		$ 1.87
Issuance cost					$ 865,567
2017 Convertible Notes [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Convertible notes bear interest at fixed rate			8.00%		8.00%
Principal amount			$ 1,540,000		$ 1,540,000
Convertible notes conversion price per common share			$ 3		$ 3
Convertible promissory notes converted into common stock		839,179
Shares of common stock issuable upon exercise of warrants		839,179
Issued new warrants exercisable common stock		839,179
Warrant exercise term		4 years 9 months 18 days
Interest on principal amount						30,800
Interest related to amortization of discounts related to bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amount						233,223
Fair value changes related to underlying premium conversion derivative and warrant liability amounted to benefit						6,265
Fair value changes related to underlying premium conversion derivative and warrant liability amounted to expense						6,689
Paulson Convertible Note Offering [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Convertible notes bear interest at fixed rate							13.00%
Principal amount	$ 3,234,800
Gross proceeds of equity qualified financing					$ 3,000,000
Equity qualified financing, description					(i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the 2019 Qualified Financing or (B) the ten day VWAP of the common stock prior to the first closing of a 2019 Qualified Financing. If a change of control transaction occurs prior to a 2019 Qualified Financing or the maturity date, the 2019 Paulson Notes would become payable on demand as of the closing date of such transaction
Description of maximum voting power of surviving entity					Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.
Warrants exercise price			$ 1.87		$ 1.87
Warrants exercisable date of issuance and expire					Nov. 1, 2022
Convertible notes to interest expense					$ 1,831,940
Warrant issuance in connection with execution note agreement	864,913				60,847
Maturity date					May 1, 2020
Interest on principal amount			$ 100,269	100,269	$ 154,144	154,144
Net valuation change of instruments measured at fair value			(31,716)	(31,716)	(31,716)	(31,716)
Net valuation of instruments measured at fair value			$ 93,858	$ 93,858	$ 93,858	$ 93,858
Warrants, description					(i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87.

Defined Contribution Plan (Deta

Defined Contribution Plan (Details) - USD ($)	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Defined Contribution Plan (Textual)
Employees defer compensation, percentage	100.00%
Employee deferrals contributions, description	The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through March 31, 2020.
Employee contributions, vesting percentage	100.00%
Employee deferrals, vesting term	6 years
Discretionary profit sharing contributions, vesting term	5 years
Contributions cost		$ (4,359)

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 531,781	$ 70,217	$ 1,119,458	$ 189,197
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	495,690	26,105	1,059,458	141,105
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 36,091	$ 44,112	$ 60,000	$ 48,092

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details 1) - Stock Options [Member]	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Offsetting Assets [Line Items]
Expected stock price volatility	54.30%	50.70%	52.80%	50.20%
Expected life of options (years)	5 years 4 months 24 days	6 years	5 years 8 months 12 days	5 years 10 months 25 days
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Risk free interest rate	1.40%	2.60%	1.70%	2.70%

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Feb. 29, 2020	Oct. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2019	Feb. 28, 2018
Restricted Stock [Member]
Stock-Based Compensation (Textual)
Stock options vested			122,767	0	133,272	0
Compensation expense associated with restricted common stock			$ 289,394	$ 0	$ 314,395	$ 0
Number of options, granted			167,851	0	167,851	0
RSUs forfeited shares			0	0	7,003	0
General and Administrative Expense [Member]
Stock-Based Compensation (Textual)
Compensation expense related to the stock awards				$ 23,563		$ 27,543
2017 Equity Incentive Plan [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share			$ 1.15	$ 1.11	$ 1.06	$ 1.12
Compensation expense related to the stock awards			$ 88,806	$ 46,654	$ 526,888	$ 46,654
Stock options vested			46,865	39,675	422,694	39,675
Number of options, granted			20,000	150,548	820,000	325,548
Unrecognized share-based expense is expected to be recognized over a weighted average period					2 years 10 months 25 days
Number of options, forfeited			260,306	0	267,803	0
Total number of stock options outstanding			1,355,512		1,355,512		845,840
Stock-Based Awards [Member]
Stock-Based Compensation (Textual)
Reserved shares of common stock for issuance								250,000
Compensation expense related to the stock awards			$ 153,581		$ 278,175
Stock options vested		60,000			0	50,000
Stock-based services expense				$ 0		$ 115,000
Common stock related to the award liability includes stock options					$ 2.30
Stock-Based Awards [Member] | Minimum [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share		$ 2
Stock-Based Awards [Member] | Maximum [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share		$ 2.65
Stock-Based Awards [Member] | Consultant [Member]
Stock-Based Compensation (Textual)
Shares of common stock	90,000	115,000
Stock-Based Awards [Member] | Consultant One [Member]
Stock-Based Compensation (Textual)
Shares of common stock	36,000	90,000
Stock Option [Member] | 2016 and 2017 Equity Incentive Plans [Member]
Stock-Based Compensation (Textual)
Unrecognized stock-based compensation			$ 800,000		$ 800,000
Shares available for future grant issuance			2,063,506		2,063,506

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Income Taxes (Textual)
Effective tax rate	0.00%	0.00%	0.00%	0.00%
Income tax benefit

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Warrant [Member]	6 Months Ended
	Mar. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Outstanding, Beginning | shares	7,265,598
Issued | shares	1,124,389
Exercised | shares
Forfeited | shares
Outstanding, Exercisable Ending | shares	8,389,987
Exercise Price Per Warrant, Issued	$ 1.87
Exercise Price Per Warrant, Exercised
Exercise Price Per Warrant, Forfeited
Weighted Average Exercise Price, Beginning	2.55
Weighted Average Exercise Price, Issued	1.87
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Exercisable Ending	$ 2.45
Outstanding, Weighted Average Term (years), Beginning	3 years 7 months 6 days
Outstanding, Weighted Average Term (years), Issued	4 years 3 months 4 days
Outstanding, Weighted Average Term (years), Ending	3 years 3 months 4 days
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price Per Warrant, Beginning	$ 1.80
Exercise Price Per Warrant, Exercisable Ending	1.80
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price Per Warrant, Beginning	3
Exercise Price Per Warrant, Exercisable Ending	$ 3

Stockholders' Deficit (Details

Stockholders' Deficit (Details Textual) - USD ($)	Dec. 12, 2018	Nov. 30, 2018	Oct. 23, 2019	Dec. 28, 2018	Mar. 31, 2019	Mar. 31, 2019
Warrant [Member]
Stockholders' Deficit (Textual)
Purchase price, per share			$ 1.80
Maximum shares to be issued under private placement			555,555
Gross proceeds from private placement			$ 255,000
Private placement transaction, description			The SEC covering the resale of the shares of common stock sold in the private placement within 60 days of the termination of the private placement.
Shares issued under private placement			141,666
Maximum potential gross proceeds from financing			$ 1,000,000
2018 Private Placement [Member]
Stockholders' Deficit (Textual)
Purchase agreement, description		(i) 1 share (each, a “Share”) of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”). The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing.
Offering price, per share	$ 2.50
Cost of issuance	$ 173,067				$ (24,029)	$ 35,665
Units sold under private placement					0	170,000
Gross proceeds from private placement	$ 1,538,000
Shares issued under private placement	615,200
2019 Private Placement [Member]
Stockholders' Deficit (Textual)
Purchase agreement, description				(i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”), to the New Purchasers. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Unit Private Placement.
Offering price, per share				$ 2.50	$ 2.50	$ 2.50
Cost of issuance				$ 1,150,359	$ 722,806	$ 812,428
Units sold under private placement					1,743,979	1,903,979
Gross proceeds from private placement				$ 5,845,448
Shares issued under private placement				2,338,179

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	May 01, 2020	Apr. 24, 2020	Apr. 30, 2020	Apr. 24, 2020	Mar. 31, 2020
Subsequent Events (Textual)
Paycheck protection program, description					The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding.
Convertible note, description					The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the "2020 Qualified Financing"), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the "Outstanding Balance") shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.
Affiliate company, description					If the Company announces a transaction between the Company and any other company (or an affiliate of any such company) that is included in the S&P 500 Health Care Index as published from time to time by S&P Dow Jones Indices LLC that includes an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration, manufacturing, distribution, licensing or supply of the Company's products (a "Strategic Transaction") before the maturity date, without any action on the part of the subscribers, the Outstanding Balance shall be converted into that number of shares of common stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the Company of a Strategic Transaction.
Outstanding voting power, percentage					50.00%
Second Paulson Amendment [Member] | Subsequent Event [Member]
Subsequent Events (Textual)
Original maturity date				May 1, 2020
Amended maturity date				Nov. 1, 2020
Notes converted amount		$ 2,633,280
2019 Paulson Notes [Member] | Subsequent Event [Member]
Subsequent Events (Textual)
Number of shares issued upon conversion	2,054,245
2020 Paulson Private Placement [Member] | Subsequent Event [Member]
Subsequent Events (Textual)
Maximum principal amount issuable under paulson private placement			$ 3,000,000
Convertible promissory notes, percentage			13.00%
Principal amount			$ 1,854,800
Convertible note, description			The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $3,000,000 or a higher amount determined by the Board.
2020 Paulson Warrant [Member]
Subsequent Events (Textual)
Exercise price, per share					$ 1.87
Warrant expired date					Apr. 30, 2023
Purchase of common stock, desciption					Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction.
2020 Paulson Private Placement [Member]
Subsequent Events (Textual)
Cash commission, percentage					12.00%
Common stock, percentage					15.00%
2020 Paulson Private Placement [Member] | Common Stock [Member]
Subsequent Events (Textual)
Exercise price, per share					$ 1.87
Broker Warrants [Member]
Subsequent Events (Textual)
Exercise price, per share					$ 1.87
Payroll Protection Program [Member]
Subsequent Events (Textual)
Loan maturity					2 years
Interest rate					1.00%
Funding loan received					$ 83,333